Prolyl hydroxylase domain (PHD) proteins, including PHD1, PHD2, and PHD3, mediate oxygen-dependent degradation of hypoxia-inducible factor (HIF) alpha subunits. Suppression of PHD enzymes leads to stabilization of HIFs and offers a potential treatment option for many ischemic disorders, such as peripheral artery occlusive disease, myocardial infarction, and stroke (1).
Hypoxia-Inducible Factor-1 (HIF-1) is a highly conserved heterodimeric transcription factor. Novus' antibody catalogue contains an extensive range of both HIF-1 alpha and HIF-1 beta, useful for hypoxia, angiogenesis, cancer and many other areas of research.
